A Randomized, Double-Blind, Placebo-Controlled Study Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Additional Health Outcomes.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Additional Health Outcomes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Methylnaltrexone bromide (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer; Progenics Pharmaceuticals; Salix Pharmaceuticals; Wyeth
  • Most Recent Events

    • 10 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.
    • 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov. (Parent trial: NCT00672139)
    • 20 Jun 2012 Lead investigator changed from Jeff Cohn to Bob Rolleri as reported by ClinicalTrials.gov (parent trial: NCT00672477).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top